Old Web
English
Sign In
Acemap
>
authorDetail
>
Hiroki Hasegawa
Hiroki Hasegawa
Eisai
Eribulin Mesylate
Oncology
Internal medicine
Trastuzumab
Taxane
2
Papers
10
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Erratum: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) (Trials (2020) 21 (391) DOI: 10.1186/s13063-020-04341-y)
2020
Trials
Toshinari Yamashita
Norikazu Masuda
Shigehira Saji
Kazuhiro Araki
Yoshinori Ito
Toshimi Takano
Masato Takahashi
Junji Tsurutani
Kei Koizumi
Masahiro Kitada
Yasuyuki Kojima
Yasuaki Sagara
Hiroshi Tada
Tsutomu Iwasa
Takayuki Kadoya
Tsuguo Iwatani
Hiroki Hasegawa
Satoshi Morita
Shinji Ohno
Show All
Source
Cite
Save
Citations (0)
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
2020
Trials
Toshinari Yamashita
Norikazu Masuda
Shigehira Saji
Kazuhiro Araki
Yoshinori Ito
Toshimi Takano
Masato Takahashi
Junji Tsurutani
Kei Koizumi
Masahiro Kitada
Yasuyuki Kojima
Yasuaki Sagara
Hiroshi Tada
Tsutomu Iwasa
Takayuki Kadoya
Tsuguo Iwatani
Hiroki Hasegawa
Satoshi Morita
Shinji Ohno
Show All
Source
Cite
Save
Citations (10)
1